Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- View the Talks
-
1. Bayesian methods in health economics: Bayesian principles 1
- Prof. Anthony O'Hagan
-
2. Bayesian methods in health economics: prior distributions 2
- Prof. Anthony O'Hagan
-
3. Bayesian methods in health economics: uncertainty in health economic evaluation 3
- Prof. Anthony O'Hagan
-
4. Bayesian methods in health economics: probabilistic sensitivity analysis 4
- Prof. Anthony O'Hagan
-
5. Bayesian methods in health economics: formulating input uncertainty 5
- Prof. Anthony O'Hagan
Printable Handouts
Navigable Slide Index
- Introduction
- Course outline
- Talk outline
- Economic modelling
- Vaccine example
- Vaccine model inputs
- The vaccine economic model
- Vaccine model outputs
- Uncertainty in economic models
- PSA
- Computing output uncertainty
- Treeage and Crystal Ball
- WinBUGS
- Monte Carlo results
- Basic PSA for the vaccine model
- When Monte Carlo is impractical
- Efficient nested Monte Carlo
- Emulation (1)
- Two model runs
- Three model runs
- Five model runs
- Emulation (2)
- Analysing the uncertainty
- Uncertainty and sensitivity
- Variance-based Sensitivity Analysis (SA)
- SA for the vaccine example
- Vaccine example - main effects
- Cost-effectiveness trajectories
- Trajectories for the vaccine model
- Value of information analysis
- VoI for the vaccine model
- Computation
- Many treatments
- Concluding remarks
Topics Covered
- Economic modelling
- Uncertainty in economic models
- Probabilistic Sensitivity Analysis (PSA)
- Computing output uncertainties
- Expressing output and decision uncertainty
- Economic model of a new vaccine
Talk Citation
O'Hagan, A. (2022, March 30). Bayesian methods in health economics: probabilistic sensitivity analysis 4 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 8, 2024, from https://doi.org/10.69645/UFAL1280.Export Citation (RIS)
Publication History
Financial Disclosures
- Tony O'Hagan acts as a consultant providing training and advice on the use of SHELF.
Bayesian methods in health economics: probabilistic sensitivity analysis 4
A selection of talks on Methods
Transcript
Please wait while the transcript is being prepared...
0:00
Hi, I'm Tony O'Hagan.
Welcome to the fourth
talk in my series,
Bayesian Methods in
Health Economics.
This talk is entitled Probabilistic
Sensitivity Analysis.
0:14
Let's quickly review one more time
the way the whole course looks.
The first two talks dealt with
Bayesian approach to statistical
inference in a general way.
Then in the third talk,
we moved on to explaining how
Bayesian methods are applied
in the area of health
economic evaluation,
and in particular, we looked at
the uncertainties in health
economic evaluation.
This talk is about probabilistic
sensitivity analysis,
which is the most important way that
health economists use Bayesian methods.
The final talk will deal with another aspect
of probabilistic sensitivity analysis,
that of formulating
input uncertainties.
0:56
Here's the road map
for this fourth talk,
we begin by discussing
economic modelling,
which is the context in which probabilistic
sensitivity analysis takes place.
We then move on to PSA itself,
and identify three key
steps in doing that.
Now, the fifth talk is entirely
devoted to one of those steps,
that of quantifying
input uncertainties.
The remainder of this talk deals
with the other two important steps.
One is computing
output uncertainties,
and finally,
how we express
those uncertainties
and how they influence
decision making.
1:31
The context, as I explained in
the previous talk, number 3,
one way that Bayesian
methods are used in
the health economic
evaluation is to analyse
the outcomes of clinical trials in which
we measure both costs and efficacy.
But as I also explained then,
this is rarely the case that health
economists find themselves in.
A single clinical trial
will rarely provide
all the evidence that you need
for cost-effectiveness study.
There are a number
of reasons for this.
First of all, let's emphasise
the single clinical trial.
Very often there is
more than one trial,
and we need to be able to combine
the information from several things.
But in that case,
almost surely some of them
will not deal with costs,
and were only
looking at efficacy.
Indeed, the common situation is where clinical
trials have only been evaluating efficacy.
Even where we have a trial in which
costs might be measured as well
the conditions of those trials are rarely what
we need for deciding on cost-effectiveness
because in a clinical
trial situation,
we invariably are looking
at limited follow-up,
and that may be very important in clinical
diseases which take some time to evolve,
we're invariably looking
at restricted enrollment,
which ensures that you get a patient group for
which you might be able to observe an effect,
whereas in the real world,
we might be wanting to use this
treatment in a wider population group.
We have in clinical trials an
unrealistic level of compliance.
The patients typically will comply
with the taking of the medicines
far more so than they would
out in their own homes.
We have the wrong
comparators very often.
We are looking at comparisons against
placebos or against treatments
that are not the ones
that we're really
comparing this treatment when
it comes to cost-effectiveness.
Finally, we very often have the
wrong outcomes in a clinical trial.
People run clinical trials in
order to demonstrate some effect,
but it may not be the effect that in economic
terms would be most valuable to see.
There are many ways in
which a clinical trial
fails to live up to what
a health economist needs
in order to evaluate
cost-effectiveness for
the treatment under
consideration
against the relevant
comparators.
Instead, health economists rely
on a process of modelling.
We look at a very simple
example in order to
Hide